Loading
A phase 3 trial of Peginterferon alfa-2b and Hydroxyurea in Polycythaemia vera, Essential thrombocythaemia and Primary myelofibrosis, run by Thomas Stauffer Larsen, completed.
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms is a phase 3 interventional study registered as NCT01387763 by Thomas Stauffer Larsen, with 202 participants recorded, started 2012-01 and reaching its primary completion in 2020-06. Interventions recorded: PegIntron, Pegasys, PegIntron, Pegasys, Hydrea. Conditions recorded: Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis.
Linked to the drug Peginterferon alfa-2b because the registry names it among its interventions and Polycythaemia vera, Essential thrombocythaemia and Primary myelofibrosis among its conditions. Registry record only: no result has been read by an editor.
Shares Peginterferon alfa-2b and the tag pipeline.
Shares Essential thrombocythaemia (ET), Polycythaemia vera (PV) and the tag pipeline.
Shares Essential thrombocythaemia (ET), Polycythaemia vera (PV) and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.
Shares Essential thrombocythaemia (ET) and the tag pipeline.